Immune Checkpoint Inhibitor Therapy- Induced Endocrinopathy
Status
Conditions
Treatments
Details and patient eligibility
About
To review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its response.
Full description
Immune checkpoint blockade-based immunotherapy is a new modality of cancer treatment with a unique mechanism that has gained increased numbers of indication and is now used in several cancer types. However, immune-related adverse events (irAEs) emerge as a new entity of diseases involving one or multiple organ systems. irAEs could result in interruption of immunotherapy, morbidities of patients or even death. Among various manifestations of irAEs, endocrinopathy and metabolic diseases are rare but important, and require prompt diagnosis and treatment to avoid life-threatening conditions.
Thus, we intend to review cases from NTUH who developed endocrinopathy and metabolic diseases after immunotherapy, and statistically analyzed their age, clinical presentation, image findings, treatment and its response. We will also review literatures to evaluate the difference and similarity from previous diagnostic and treatment experience.
Enrollment
Sex
Ages
Volunteers
Inclusion criteria
- Patients who receive immunotherapy in NTUH and develop endocrinopathy after therapy
Exclusion criteria
- Patients less than 20 years old. Patients who are pregnant
Trial design
200 participants in 1 patient group
Trial contacts and locations
Loading...
Central trial contact
Shyang-Rong Shih
Data sourced from clinicaltrials.gov
Clinical trials
Research sites
Resources
Legal